# Modi Ventures

> Modi Ventures is a VC fund in Houston backing Health Care and Biotechnology. See 30 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Houston, United States
- Total investments: 30
- Last investment: May 2026
- Lead investor: 17%
- Last fund: Jul 2025
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/modi-venture-partners/
- Website: https://www.modivc.com

Modi Ventures is a Texas-based investment firm investing in fund managers and founders building companies shaping the future of humanity. The company's primary investment focus is into disruptive and emerging AI and Medical technology applications. Investments in successful funds include Khosla Ventures, Section 32, Artis Ventures, DraperAssociates and Antler Global. Direct investments include, Starling Medicine and Cyberdontics. For more information please visit www.modivc.com.

## Contacts

5 contacts available for Modi Ventures. Shizune tracks 1 team members at Modi Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/modi-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 12 | 40% |
| Biotechnology | 11 | 37% |
| Medical | 6 | 20% |
| Artificial Intelligence | 6 | 20% |
| Life Science | 4 | 13% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 37% |
| Seed | 7 | 23% |
| Series B | 3 | 10% |
| Funding Round | 2 | 7% |
| Series C | 1 | 3% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 53% |
| United Kingdom | 3 | 10% |
| Germany | 1 | 3% |
| The Netherlands | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Sahirzeeshan Ali | Founder and General Partner | 5 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Imagenomix | Imagenomix is a cancer diagnostics startup by enhancing trial enrollment and creates access to targeted therapy. | $3.2M | Seed | May 07, 2026 |  |
| Cytospire Therapeutics | Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M | Series A | May 05, 2026 |  |
| Latus Bio | Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing. | $43M | Series A | May 04, 2026 |  |
| Brainomix | Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $6.5M | Series C | Feb 24, 2026 |  |
| Exciva | exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M | Series B | Jan 20, 2026 |  |
| Proxima | Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M | Seed | Jan 13, 2026 |  |
| Lila Sciences | Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $115M | Series A | Oct 14, 2025 |  |
| Lila Sciences | Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $235M | Series A | Sep 14, 2025 |  |
| RBL | RBL is a biotech venture creation studio designed to rapidly build companies based on life-saving medical technologies.. |  | Seed | Aug 08, 2025 |  |
| Lila Sciences | Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $200M | Seed | Mar 10, 2025 |  |

10 of 30 investments shown.

## Co-investors
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 9 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 5 deals together
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund, 4 deals together
- [March Capital](https://shizune.co/investors/profile/march-capital-partners) — VC Fund, 4 deals together
- [LifeArc Ventures](https://shizune.co/investors/profile/lifearc-ventures) — VC Fund, 3 deals together
- [NVentures](https://shizune.co/investors/profile/nventures-0731) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Modi Ventures invest in?

Modi Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Modi Ventures?

Public channels for Modi Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Modi Ventures?

The team at Modi Ventures includes Sahirzeeshan Ali (Founder and General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co